Biobanking has emerged as a strategic challenge to promote knowledge on neurological diseases, by the application of translational research. Due to the inaccessibility of the central nervous system, the advent of biobanks, as structure collecting biospecimens and associated data, are essential to turn experimental results into clinical practice. Findings from basic research, omics sciences, and in silico studies, definitely require validation in clinically well-defined cohorts of patients, even more valuable when longitudinal, or including preclinical and asymptomatic individuals. Finally, collecting biological samples requires a great effort to guarantee respect for transparency and protection of sensitive data of patients and donors. Since the European General Data Protection Regulation 2016/679 has been approved, concerns about the use of data in biomedical research have emerged. In this narrative review, we focus on the essential role of biobanking for translational research on neurodegenerative diseases. Moreover, we address considerations for biological samples and data collection, the importance of standardization in the preanalytical phase, data protection (ethical and legal) and the role of donors in improving research in this field.
AchironAGrottoIBalicerRMagalashviliDFeldmanAGurevichM.2010. Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis. Neurobiol Dis38(2):201–9.
2.
AlbertMSDeKoskySTDicksonDDuboisBFeldmanHHFoxNC others. 2011. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association Workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7(3):270–9.
3.
BaberRKiehntopfM.2019. Automation in biobanking from a laboratory medicine perspective. J Lab Med43(6):329–38.
4.
BakerM. 2016. 1,500 scientists lift the lid on reproducibility. Nature533(7604):452–4.
5.
BetsouFLehmannSAshtonGBarnesMBensonEECoppolaD others. 2010. Standard preanalytical coding for biospecimens: defining the sample preanalytical code. Cancer Epidemiol Biomarkers Prev19(4):1004–11.
6.
BlennowKHampelHWeinerMZetterbergH.2010. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol6(3):131–44.
7.
BoniniPPlebaniMCeriottiFRubboliF.2002. Errors in laboratory medicine. Clin Chem48(5):691–8.
8.
BosisioFBarazzettiGKoutaissoffDSpencerB.2021. Patients’ decision to contribute to a biobank in the light of the patient-recruiter relationship–a qualitative study of broad consent in a hospital setting. J Community Genet12(1):15–25.
9.
BoxerALYuJTGolbeLILitvanILangAEHöglingerGU. 2017. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 16(7):552–63.
10.
BreierMWahlSPrehnCFugmannMFerrariUWeiseM others. 2014. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PLoS One9(2):e89728.
11.
CampbellLDAstrinJJDeSouzaYGiriJPatelAARawley-PayneM others. 2018. The 2018 revision of the ISBER best practices: summary of changes and the editorial team’s development process. Biopreserv Biobank16(1):3–6.
12.
CoorsMEWestfallNZittlemanLTaylorMWestfallJM. 2018. Translating biobank science into patient-centered language. Biopreserv Biobank16(1):59–63.
De SouzaYGGreenspanJS. 2013. Biobanking past, present and future: responsibilities and benefits. AIDS27(3):303–12.
16.
De VriesRGTomlinsonTKimHMKrenzCDRyanKALehpamerNandothers. 2016. The moral concerns of biobank donors: the effect of non-welfare interests on willingness to donate. Life Sci Soc Policy12:3.
17.
DurantTJSGongGPriceNSchulzWL. 2020. Bridging the collaboration gap: real-time identification of clinical specimens for biomedical research. J Pathol Inform11:14.
18.
EderJGottweisHZatloukalK.2012. IT solutions for privacy protection in biobanking. Public Health Genomics15(5):254–62.
19.
ElkordE. 2009. Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation. J Immunol Methods347(1–2):87–90.
20.
EnrothSHallmansGGrankvistKGyllenstenU.2016. Effects of long-term storage time and original sampling month on biobank plasma protein concentrations. EBioMedicine12:309–14.
21.
FlorellSRCoffinCMHoldenJAZimmermannJWGerwelsJWSummersBK others. 2001. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol14(2):116–28.
22.
Gayet-AgeronARudazSPernegerT. (2017). Biobank attributes associated with higher patient participation: a randomized study. Eur J Hum Genet25(1):31–6.
23.
GBD 2015 Neurological Disorders Collaborator Group. 2017. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol16(11):877–97.
24.
GBD 2016 Neurology Collaborators. 2019. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol18(5):459–80.
25.
GiampieriM. 2012. Communication and informed consent in elderly people. Minerva Anestesiol78(2):236–42.
26.
GilleFAxlerRBlasimmeA.2021. Transparency about governance contributes to biobanks’ trustworthiness: call for action. Biopreserv Biobank. 19(1):83–5.
27.
GottweisHGaskellGStarkbaumJ.2011. Connecting the public with biobank research: reciprocity matters. Nat Rev Genet12(11):738–9.
28.
GuerinJSMurrayDWMcGrathMMYuilleMAMcPartlinJMDoranPP. 2010. Molecular Medicine Ireland guidelines for standardized biobanking. Biopreserv Biobank8(1):3–63.
29.
GuoDWangAXieTZhangSCaoDSunJ.2020. Effects of ex vivo ischemia time and delayed processing on quality of specimens in tissue biobank. Mol Med Rep22(5):4278–88.
30.
HallinanD. 2020. Broad consent under the GDPR: an optimistic perspective on a bright future. Life Sci Soc Policy16(1):1.
31.
HallinanD. 2021. Biobank oversight and sanctions under the general data protection regulation. In: SlokenbergaSTzortzatouOReichelJ, editors). GDPR and biobanking. Law, governance and technology series, Vol 43. Springer; pp. 121–44.
32.
HarishGVenkateshappaCMahadevanAPruthiNBharathMMShankarSK. 2011. Effect of storage time, postmortem interval, agonal state, and gender on the postmortem preservation of glial fibrillary acidic protein and oxidatively damaged proteins in human brains. Biopreserv Biobank9(4):379–87.
33.
Hok-A-HinYSWillemseEAJTeunissenCEDel CampoM.2019. Guidelines for CSF processing and biobanking: impact on the identification and development of optimal CSF protein biomarkers. Methods Mol Biol2044:27–50.
34.
JackCRBennettDABlennowKCarrilloMCDunnBHaeberleinSB others. 2018. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement14(4):535–62.
35.
KinkorováJ. 2015. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: overview. EPMA J. 7:4.
36.
LaBaerJMiceliJFFreedmanLP. 2018. What’s in a sample? Increasing transparency in biospecimen procurement methods. Nat Methods15(5):303–4.
37.
LeeJEKimSYShinSY. 2015. Effect of repeated freezing and thawing on biomarker stability in plasma and serum samples. Osong Public Health Res Perspect6(6):357–62.
38.
LeitãoMJBaldeirasIHerukkaSKPikkarainenMLeinonenVSimonsenAH others. 2015. Chasing the effects of pre-analytical confounders—a multicenter study on CSF-AD biomarkers. Front Neurol6:153.
39.
Lindestam ArlehamnCSDhanwaniRPhamJKuanRFrazierARezende DutraJ others. 2020. Α-synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun. 11(1):1875.
40.
LinsenLVan LanduytKEctorsN.2019. Automated sample storage in biobanking to enhance translational research: the bumpy road to implementation. Front Med (Lausanne). 6:309.
41.
LippiGGuidiGCMattiuzziCPlebaniM.2006. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med44(4):358–65.
42.
LunshofJEChurchGMPrainsackB.2014. Information access. Raw personal data: providing access. Science343(6169):373–4.
MarshFH. 1986. Informed consent and the elderly patient. Clin Geriatr Med2(3):501–10.
45.
MickePOhshimaMTahmasebpoorSRenZPOstmanAPonténF others. 2006. Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. Lab Invest86(2):202–11.
46.
NeubauerTHeurixJ.2011. A methodology for the pseudonymization of medical data. Int J Med Inform80(3):190–204.
47.
NeubauerTRiedlB.2008. Improving patients privacy with pseudonymization. Stud Health Technol Inform136:691–6.
48.
PalmqvistSTidemanPCullenNZetterbergHBlennowKDageJL others. 2021. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med27(6):1034–42.
49.
PaskalWPaskalAMDębskiTGryziakMJaworowskiJ.2018. Aspects of modern biobank activity—comprehensive review. Pathol Oncol Res24(4):771–85.
50.
PeloquinDDiMaioMBiererBBarnesM.2020. Disruptive and avoidable: GDPR challenges to secondary research uses of data. Eur J Hum Genet28(6):697–705.
51.
PittKECampbellLDSkubitzAPNAamodtRAnounaABairdP others. (2005). Best practices for repositories I: collection, storage, and retrieval of human biological materials for research. Cell Preserv Technol3(1):5–48.
52.
RaivolaVSnellKHelénIPartanenJ.2019. Attitudes of blood donors to their sample and data donation for biobanking. Eur J Hum Genet27(11):1659–67.
53.
RundgrenIMBruserudØRyningenAErsværE.2018. Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood. J Immunol Methods461:53–62.
54.
SancesarioGBernardiniS.2019. AD biomarker discovery in CSF and in alternative matrices. Clin Biochem72:52–7.
55.
SancesarioGMBernardiniS.2018. Diagnosis of neurodegenerative dementia: where do we stand, now?Ann Transl Med6(17):340.
56.
SancesarioGMEspositoZNuccetelliMBernardiniSSorgeRMartoranaA others. 2010. Aβ1-42 detection in CSF of Alzheimer’s disease is influenced by temperature: indication of reversible Aβ1-42 aggregation?Exp Neurol223(2):371–6.
57.
SomiariSBSomiariRI. 2015. The future of biobanking: a conceptual look at how biobanks can respond to the growing human biospecimen needs of researchers. Adv Exp Med Biol864:11–27.
58.
SperlingRAAisenPSBeckettLABennettDACraftSFaganAM others. 2011. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association Workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7(3):280–92.
59.
StauntonCSlokenbergaSMascalzoniD.2019. The GDPR and the research exemption: considerations on the necessary safeguards for research biobanks. Eur J Hum Genet27(8):1159–67.
60.
StockerHNabersAPernaLMöllersTRujescuDHartmannA others. 2020. Prediction of Alzheimer’s disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to apoe4 status, and other risk factors. Alzheimers Dement16(2):283–91.
61.
SunHSunRHaoMWangYZhangXLiuY others. 2016. Effect of duration of ex vivo ischemia time and storage period on RNA quality in biobanked human renal cell carcinoma tissue. Ann Surg Oncol23(1):297–304.
62.
Takai-IgarashiTKinoshitaKNagasakiMOgishimaSNakamuraNNagaseS others. 2017. Security controls in an integrated biobank to protect privacy in data sharing: rationale and study design. BMC Med Inform Decis Mak17(1):100.
63.
TeunissenCEPetzoldABennettJLBervenFSBrundinLComabellaM others. 2009. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology73(22):1914–22.
64.
TeunissenCETumaniHEngelborghsSMollenhauerB.2014. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem47(4–5):288–92.
65.
WeinbergASongLYWilkeningCSevinABlaisBLouzaoR others. 2009. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol16(8):1176–86.
66.
WeintraubWSFahedACRumsfeldJS. 2018. Translational medicine in the era of big data and machine learning. Circ Res123(11):1202–4.
67.
YangJDiazNAdelsbergerJZhouXStevensRRupertA others. 2016. The effects of storage temperature on PBMC gene expression. BMC Immunol17:6.
